Bertelsmann India Investments

Bertelsmann India Investments is the strategic investment arm of Bertelsmann SE, the German media and services conglomerate, focused on high-growth Indian digital and technology businesses. Stage focus is Series B through growth with checks in the $5M to $25M range, and AI is not flagged as a primary focus. Healthcare interest expresses through digital health and tech-enabled care delivery, often in larger growth rounds where Bertelsmann participates alongside Indian and global PE-style investors. The fund has a long Indian operating history and is one of the more institutionally credible CVC platforms in the country. The right founder is the CEO of a maturing Indian healthcare or healthtech business with $10M+ in ARR or equivalent gross profit metrics, clear path to scale, and the governance maturity to absorb growth capital from a corporate investor with global compliance standards. The wrong founder is a Series A or earlier company, a regulated medtech or biotech team, or a US-based founder without an Indian operating thesis. Intro paths run through Mumbai and Delhi institutional capital networks, investment banks active in Indian healthcare such as Avendus, JM Financial, and Allegro, frequent co-investors such as TPG Growth, Bain Capital India, ChrysCapital, and Multiples, and through Bertelsmann’s existing portfolio CEOs many of whom are publicly active. Direct outreach to BII is acknowledged but the firm’s deal cadence is overwhelmingly relationship-driven within India’s tight growth-capital community. In the pitch, lead with audited financials, the use of proceeds tied to specific scaling levers including Tier-2 and Tier-3 expansion or M&A consolidation, and a clear-eyed view of the path to Series C, Series D, or pre-IPO. Show that you understand Indian healthcare exit dynamics, where IPO on NSE or BSE is the dominant outcome and strategic acquisition is rarer. Be specific about CDSCO, NPPA, NMC, and DPDPA compliance posture. Caveats include the longer diligence cycles typical of strategic CVCs operating to global compliance standards, the inherent tensions of corporate venture including potential information-rights complexity, and the reality that Bertelsmann’s healthcare interest sits within a broader media-and-services thesis, so deal cadence in pure healthcare is uneven. For maturing Indian healthcare businesses, BII is a credible institutional partner with global brand value.